Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Decera Clinical Education Oncology Podcast · Feb 10, 2025 · 20m

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

Early results with teclistamab combined with anti-CD38 therapy

Real-world data with teclistamab including its use after other BCMA-targeted therapies

Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy

Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

Presenter:

Shaji K. Kumar, MD

Mark…